Morgan Stanley’s Evoke Pharma EVOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-159,358
| Closed | -$792K | – | 8285 |
|
|
2025
Q3 | $792K | Buy |
159,358
+159,294
| +248,897% | +$790K | ﹤0.01% | 5280 |
|
|
2025
Q2 | $166 | Hold |
64
| – | – | ﹤0.01% | 7595 |
|
|
2025
Q1 | $176 | Buy |
64
+33
| +106% | +$140 | ﹤0.01% | 7486 |
|
|
2024
Q4 | $137 | Hold |
31
| – | – | ﹤0.01% | 7443 |
|
|
2024
Q3 | $148 | Hold |
31
| – | – | ﹤0.01% | 7404 |
|
|
2024
Q2 | $198 | Hold |
31
| – | – | ﹤0.01% | 7301 |
|
|
2024
Q1 | $229 | Sell |
31
-32
| -51% | -$272 | ﹤0.01% | 7302 |
|
|
2023
Q4 | $788 | Buy |
+63
| New | +$936 | ﹤0.01% | 7234 |
|
|
2023
Q1 | – | Sell |
-1
| Closed | -$19 | – | 7751 |
|
|
2022
Q4 | $19 | Buy |
+1
| New | +$22 | ﹤0.01% | 7776 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 7747 |
|
|
2022
Q2 | – | Sell |
-43
| Closed | -$3K | – | 7850 |
|
|
2022
Q1 | $3K | Sell |
43
-24
| -36% | -$1.91K | ﹤0.01% | 7680 |
|
|
2021
Q4 | $5K | Sell |
67
-721
| -91% | -$101K | ﹤0.01% | 7639 |
|
|
2021
Q3 | $148K | Sell |
788
-3,258
| -81% | -$549K | ﹤0.01% | 6151 |
|
|
2021
Q2 | $798K | Sell |
4,046
-981
| -20% | -$210K | ﹤0.01% | 5218 |
|
|
2021
Q1 | $1.32M | Buy |
5,027
+1,527
| +44% | +$611K | ﹤0.01% | 4549 |
|
|
2020
Q4 | $1.3M | Buy |
3,500
+2,855
| +443% | +$1.47M | ﹤0.01% | 4497 |
|
|
2020
Q3 | $436K | Buy |
645
+461
| +251% | +$294K | ﹤0.01% | 4711 |
|
|
2020
Q2 | $93K | Buy |
184
+181
| +6,033% | +$50.3K | ﹤0.01% | 5435 |
|
|
2020
Q1 | $1K | Sell |
3
-7
| -70% | -$1.34K | ﹤0.01% | 6457 |
|
|
2019
Q4 | $2K | Hold |
10
| – | – | ﹤0.01% | 6497 |
|
|
2019
Q3 | $1K | Sell |
10
-53
| -84% | -$7.1K | ﹤0.01% | 6542 |
|
|
2019
Q2 | $5K | Buy |
63
+3
| +5% | +$297 | ﹤0.01% | 6304 |
|
|
2019
Q1 | $13K | Sell |
60
-48
| -44% | -$16.4K | ﹤0.01% | 6120 |
|
|
2018
Q4 | $39K | Sell |
108
-1
| -0.9% | -$370 | ﹤0.01% | 5823 |
|
|
2018
Q3 | $46K | Buy |
109
+78
| +252% | +$31.1K | ﹤0.01% | 5896 |
|
|
2018
Q2 | $11K | Hold |
31
| – | – | ﹤0.01% | 6280 |
|
|
2018
Q1 | $9K | Sell |
31
-6
| -16% | -$1.97K | ﹤0.01% | 6282 |
|
|
2017
Q4 | $12K | Sell |
37
-4
| -10% | -$1.66K | ﹤0.01% | 6185 |
|
|
2017
Q3 | $20K | Buy |
41
+17
| +71% | +$6.56K | ﹤0.01% | 6028 |
|
|
2017
Q2 | $9K | Sell |
24
-34
| -59% | -$13K | ﹤0.01% | 6262 |
|
|
2017
Q1 | $26K | Buy |
58
+43
| +287% | +$17.6K | ﹤0.01% | 6008 |
|
|
2016
Q4 | $4K | Buy |
15
+12
| +400% | +$3.11K | ﹤0.01% | 6298 |
|
|
2016
Q3 | $1K | Buy |
+3
| New | +$1.37K | ﹤0.01% | 6417 |
|
|
2015
Q3 | – | Sell |
-12
| Closed | -$9K | – | 6637 |
|
|
2015
Q2 | $9K | Buy |
12
+5
| +71% | +$4.26K | ﹤0.01% | 6316 |
|
|
2015
Q1 | $7K | Hold |
7
| – | – | ﹤0.01% | 6292 |
|
|
2014
Q4 | $6K | Buy |
+7
| New | +$5.78K | ﹤0.01% | 6297 |
|
|
2014
Q3 | – | Sell |
-3
| Closed | -$4K | – | 6587 |
|
|
2014
Q2 | $4K | Hold |
3
| – | – | ﹤0.01% | 6314 |
|
|
2014
Q1 | $4K | Sell |
3
-125
| -98% | -$178K | ﹤0.01% | 6273 |
|
|
2013
Q4 | $137K | Buy |
+128
| New | +$183K | ﹤0.01% | 5216 |
|
Morgan Stanley's EVOK Position: Q4 2025 in Review
Morgan Stanley sold out of Evoke Pharma (EVOK) in Q4 2025, closing a stake of 159,358 shares — an estimated $792K sold.
Morgan Stanley first reported a position in EVOK in Q4 2013 and held it in 38 quarters. The position peaked at $1.32M in Q1 2021. 0 funds tracked by Wall St. Rank hold EVOK as of Q4 2025.
- Morgan Stanley reported no remaining Evoke Pharma position as of Q4 2025 after selling out during the quarter.
- Morgan Stanley sold 159,358 Evoke Pharma shares in Q4 2025, an estimated $792K.
- Morgan Stanley first reported a position in Evoke Pharma in Q4 2013 and held it in 38 quarters.
- Morgan Stanley's Evoke Pharma position peaked at $1.32M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2025.
Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.